Peter Langmuir, MD
Advertisement
Articles by Peter Langmuir, MD
eter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses the vandetanib clinical trials.
Advertisement
Latest Updated Articles
Dr. Langmuir Discusses Vandetanib Clinical TrialsPublished: March 15th 2011 | Updated:
Dr. Langmuir Explains the Side Effects of VandetanibPublished: April 7th 2011 | Updated:
Vandetanib Advantages in Medullary Thyroid CancerPublished: March 15th 2011 | Updated:
Dr. Langmuir on Vandetanib in Medullary Thyroid CancerPublished: March 15th 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5